An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems for the management of diabetes and metabolic health in the United States an…
VERDICT
The label
Markup
read at $74.85
Dexcom holds its Markup at $74.85.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-29
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 69 days
Price
$74.85
Valuation
31.45 trailing · 24.32 forward price to earnings
Values screen
PASS· score 75.9
Beta
1.45
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads OVERVALUED — it trades at roughly a 2% discount to our $76.35 fair value, moderate competitive moat, 15.00% revenue growth.
Read at
$74.85
31.45 P/E · 24.32 fwd
Our fair value
$76.35
2% discount
Analyst target (avg)
$85.00
+14% to current
Target low $65.00Analyst target rangeTarget high $112.00
▲ current $74.85 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$74.85
you are here
Conservative
$58.50
-22%
Analyst avg
$85.00
+14%
Our fair value
$76.35
+2%
Analyst high
$112.00
+50%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Our more conservative model reads it as roughly fairly valued here, while the Street is more bullish — a quality-at-a-fair-price name rather than a deep-value one.
Revenue growth
15.00%
Profit margin
19.31%
Debt to equity
46.83
Analyst consensus
Strong Buy · 25 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 21.9% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 3.4% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 33.7% of assets, under the 49% limit.Pass
Revenue purityOnly 2.4% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Glucose monitors track steady growth at full price
Anyone managing diabetes knows the relief of a sensor that removes constant finger pricks. Dexcom supplies that with its G7 systems and delivers revenue growth of 15 percent alongside a 19 percent profit margin and 36 percent return on equity. The business passes our ethical screen and holds a moderate moat in continuous glucose monitoring.
Yet the shares sit at our fair value of 76.35 dollars with zero margin of safety. Forward earnings sit at 24.9 times, which matches the growth on offer but offers no cushion if adoption slows.
Analysts cluster around an 85 dollar target, yet that optimism assumes the current pace continues without fresh competition or reimbursement pressure. The setup leaves little room for disappointment.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
DXCM trades on a US exchange. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 11%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (25 analysts) rates it strong buy, with a mean price target of $82. Entered 2026-07-27 · Markup
JOURNAL
The dated journal · newest first, never edited
2026-07-27Markup$76.65+5.2%Entry 4
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 5.2% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 11%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (25 analysts) rates it strong buy, with a mean price target of $82.
2026-07-18Markup$72.86+0.0%Entry 3
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 11%. Our forward projection puts the odds of a 10% gain over the next month near 23%. The street (25 analysts) rates it strong buy, with a mean price target of $82.
2026-07-03Markup$72.86+0.0%Entry 2
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Markup$72.86Entry 1
The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.